Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PEPD | P12955 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071925 | 0.85 | HCRTR2 (0.33) | KDM4ELIPELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9928395 | 0.85 | HCRTR2 (0.33) | KDM4ELIPELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL25322253 | 0.83 | POLB (0.41) | LIPELMNAALDH1A1MAPT | |
| SCHEMBL17892791 | 0.83 | POLB (0.41) | LIPELMNAALDH1A1MAPT | |
| SCHEMBL9895421 | 0.83 | POLB (0.41) | LIPELMNAALDH1A1MAPT | |
| SCHEMBL9898712 | 0.80 | THRB (0.33) | LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL23189624 | 0.78 | — | — | |
| SCHEMBL18546124 | 0.77 | HTT (0.34) | KDM4ESMN1; SMN2 | |
| SCHEMBL8007592 | 0.77 | NR1H2 (0.40) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17686396 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470525-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | KDM4E 499/4885LIPE 1828/4885DPP4 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.